A Real-life Study of the Positive Response to DAA-based Therapies for Hepatitis C in Brazil

Simone Monzani Vivaldini^{1,2*}; Rachel Abraão Ribeiro¹; Gláucio Mosimann Júnior¹; Karen Cristine Tonini¹; Gerson Fernando Mendes Pereira¹; Wildo Navegantes de Araújo ^{2,3,4}.

1 Department of Chronic Conditions Diseases and other Sexually Transmitted Infections, Secretariat for Health Surveillance, Ministry of Health – Brasília/DF, Brazil.

2 Center for Tropical Medicine, Faculty of Medicine, University of Brasília (UnB), Brasília/DF, Brazil

3 National Institute for Science and Technology for Health Technology Assessment, Porto Alegre/RS, Brazil.

4 Faculty of Ceilândia, University of Brasília (UnB), Brasília/DF, Brazil

*Corresponding author: simonevivaldini@gmail.com

Abstract

Treating hepatitis C virus (HCV) infections reduces overall mortality and the risk of multiple extrahepatic complications. Direct-acting antivirals (DAAs) are molecules that target specific non-structural proteins of the virus, resulting in the disruption of viral replication and infection. This report describes the activities undertaken to assess the cure of HCV in patients of different age groups, supported by the Viral Hepatitis National Program of the Unified Health System in Brazil.

Around 11,000 patients wereevaluated in an electronic retrospective cohort, which used therapeutic schemes with Sofosbuvir (SOF), Daclatasvir (DCV), Simeprevir (SMV), and an association of Ombitasvir, Veruprevir/Ritonavir and Dasabuvir (3D) with or without Ribavirin NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

(RBV), with sustained virologic response (SVR) or viral cure after a 12-week treatment. We conducted logistic regressions to identify factors independently associated with positive response to DAA-based therapies.

Among evaluated patients, 57.1% were male; 48.3% identified as white; 78.3% were over 50 years old; 44.1% were from the Southeast region; 47.7% had genotype 1b; and 84.5% were treated for 12 weeks. The SVR rates with DAAs ranged from 87% to 100%. Genotypes 1 and 4 had a better response (96.3 to 100% of SVR) to therapy with DAAs, and genotypes 2 and 3 had SVR of 90.6% to 92.2%. Different treatment periods showed SVR with an average of 95.0% and 95.9% for 12 and 24 weeks, respectively. In the odds ratio assessment, we verified that females were half as likely (OR 0.5; CI 95% 0.4-0.6) to have a negative response to therapy, when compared to males, and that genotypes 2 and 3 were around twice more likely (OR 1.5-2.2; CI 95% 0.7-2.9; 1.2-3.6 and OR 2.7-2.8; CI 95% 2.0-3.8, respectively) to not have SVR after therapy when compared to genotype 1. Patients aged between 50 and 69 years old were 1.2 times (OR 1,2; CI95% 0,7-1,9) more likely to not have SVR when treated with DAAs, when compared to other age groups.

This study is the first of this magnitude to be held in a Latin-American country with high SVR results, supported by a free-of- charge universal and public health system. We confirm the high performance of DAA-based therapies which support the Brazilian public health policy decision of adopting them as an important part of the country's strategy to eliminate HCV by 2030.

Key words: hepatitis C, treatment, direct-acting antivirals, health policy, Brazil.

1

2 Introduction

Globally, there are an estimated 71 million people with chronic hepatitis C virus (HCV)
infection and only a small minority were able to access curative treatment in 2016 ^[1, 2]. Due to
the substantial impact of hepatitis C virus (HCV) infection globally on patients, their families,

and public health systems, the World Health Organization (WHO) has set HCV elimination
goals that include the reduction of HCV incidence by 80% and HCV-related mortality by 65%
before 2030 ^[1, 3]. As part of the strategy to achieve these goals, WHO included all-oral,
interferon-free, direct-acting antiviral (DAA) regimens in its 2017 edition ^[1, 3, 4].

10 About 632,000 people in Brazil are infected with HCV, with seroprevalence of 0.70 in the population aged between 15 and 69 years ^[5]. Most HCV-infected people are unaware of 11 12 their status until the virus has caused serious liver damage ^[3,6,7]. The introduction of DAAs in 2015 has changed the landscape of treatment and its associated outcomes in the Brazilian 13 Unified National Health System (SUS)^[6]. Despite the high potency of DAAs, their high cost 14 15 initially represented a serious barrier, leading to the rationing of HCV treatment for patients with high risk of disease progression and the development of complications ^[7, 8, 9, 10, 11]. 16 17 However, today all Brazilian patients have access to these therapies.

18 Brazil's National Report for HCV treatment was launched in 2015, elaborated by the Brazilian Ministry of Health (MoH-Brazil), and adopted by SUS^[6]. In 2018, the MoH-Brazil 19 20 took a step forward to support the development and implementation of national multi-sector 21 policies and strategies for hepatitis prevention and control in Brazil, for all HCV-infected patients, regardless of the degree of liver fibrosis^[12]. Since many countries are working on 22 23 action plans to address HCV, different methodologies, processes, and ways to move forward 24 have been identified. Therefore, the analysis and comparison of Brazil's policies may offer an opportunity to accelerate the development and implementation of new national plans^[13]. SUS 25 26 supported the annual cost per capita of US\$ 6,152.85 on average for DAA-based therapies from 2015 to 2018^[14]. The Ministry of Health has developed a mathematical model to better 27 28 understand the national prevalence data and establish its own elimination goals, including an estimation of the number of people to be treated [5,15]. 29

Since the isolation of the hepatitis C virus in 1989, several strategies to eliminate the infection have been studied. Interferon was the first drug used for treatment, having been used for many years. The addition of Ribavirin allowed the achievement of sustained virologic response (SVR) rates of around 55%. The most important change occurred with the introduction of DAAs: shorter treatments, oral use, and general SVR rates above 95% ^[15]. The purpose of this study is to determine the impact of DAA regimens within all 27 Brazilian states and to identify the factors associated with SVR.

37

38 Materials and Methods


39 A retrospective cohort study was conducted using different national databases of the 40 Brazilian Public Health System, including the diagnostic information system (GAL), hospital 41 information system (SIH), and treatment information system (HORUS). The population for 42 this study included people with acute or chronic hepatitis C, most of them with important 43 comorbidities. They were part of the first groups treated by the Brazilian National Health 44 System (SUS) with therapeutic schemes which sometimes employed Ribavirin (RBV) and/or 45 Peginteferon alfa-2a (PEG) but, in most cases, were composed of direct-acting antivirals: 46 Sofosbuvir (SOF), Daclatasvir (DCV), Simeprevir (SMV) or 47 Ombitasvir/Veruprevir/Ritonavir+Dasabuvir (3D). These drugs used different therapeutic 48 combinations: SOF+DCV±RBV; SOF+SMV±RBV; SOF+RBV; 3D±RBV; SOF+PEG+RBV. 49 Treatments conducted exclusively with Peginteferon alfa-2a and Ribavirin were also included 50 with the objective of obtaining a comparative reference to DAA-based treatments.

51 To obtain the final database with the selected population, two steps were developed. 52 The first step consisted of identifying a probabilistic relationship among the following 53 databases: (i) Laboratory Environment Management System (GAL) – which contains data from 54 the Central Laboratories of Public Health (LACEN); (ii) SUS Ambulatory Information System

55 (SIA/SUS) - which includes records from the High Complexity Procedures Authorization 56 (APAC) database; and (iii) Individual Outpatient Production Bulletins (BPAI) – which contain information recorded by states concerning requests and delivery of medication. From this 57 58 relationship, a unique numeric code (ID) was attributed to each patient and this code was 59 replicated in the different databases to allow the connection of the information taken from 60 different sources. Later, patients' personal data were suppressed to maintain anonymity. This step was developed by the SUS Department of Information Technology (DATASUS) through 61 a project called "VinculaSUS"^[19], whose objective is to facilitate researchers' analyses of 62 policies developed by the Brazilian Ministry of Health while maintaining ethical commitments 63 64 and the confidentiality of personal data. 65 The second step consisted of selecting patients with at least one viral load count by quantitative real-time qPCR-HCV test from the GAL database and some record of treatment 66 67 for HCV in the SIA/SUS database, filtering patients who had detectable qPCR-HCV following 12 weeks of treatment and assessing how many of these patients presented SVR to HCV. Figure 68 69 1 details the procedures and quantifies the results of the first and second steps. 70 71 72

- 73
- 74
- 75
- 76
- 77
- 78

79 **Figure 1.** Relationship information from the databases used and final identification of 11,308



81

82 patients who completed the post-treatment investigation (quantitative qPCR-HCV test).

From the final database, descriptive analyses were performed with the objective of understanding the studied population and the procedures of interest that were adopted. All available sociodemographic, clinical, and laboratory variables were analyzed: sex, age, race/color, place of residence, genotype, time of treatment, therapeutic scheme, start and end date of treatment, date of laboratory tests, and respective results of qPCR-HCV tests. Trend and dispersion measures were used for numerical variables, and rates or proportions were utilized for categorical variables.

Patients were spatially distributed into three groups: 1) those registered in the APAC
database who had at least one exam registered in the GAL database; 2) those registered in the
APAC database who had at least one exam 12 weeks after the end of treatment registered in

GAL; and 3) those registered in the APAC database who had at least one exam 12 weeks after
the end of the treatment registered in GAL and who had reached SVR.

Some criteria were used to make the analyzed groups more homogeneous and to promote greater internal validity: analyses separated by genotypes; evaluation of therapeutic schemes; treatment time; and results of qPCR-HCV tests evaluated after 12 weeks of treatment completion. We compared the proportions to assess whether the results were statistically significant. Pearson's chi-squared test was applied with a significance level of $\alpha = 5\%$. We used the odds ratio (OR) and confidence interval (CI) of 95% to identify the factors associated with SVR.

102 A bivariate analysis was conducted to assess the relationships between positive and 103 negative responses to therapy and the available sociodemographic data, along with some of the 104 comorbidities. For the multivariate analysis, we used the variables that presented a p-value < 105 0.2 in the bivariate analysis. We identified collinearity in two variables using a correlation matrix, and variables that presented $R^2 > 0.5$ were selected. Three different models were 106 107 evaluated through the Akaike Information Criterion (AIC), and a multivariate model of logistic 108 regression was defined to determine the independent association between SVR responses to 109 therapy (cure vs no cure). These responses were defined by the results of the qPCR-HCV test 110 as undetectable (SVR) or detectable (not SVR).

All statistical analyses were conducted using SPSS 20.0 for Windows, with a significance level of 0.05 (Table 2a e 2b). Statistical analyses and graphical representations were performed using the IBM-PASW Statistics version 18 and Microsoft Excel® 2013 programs. Analysis and maps were developed utilizing RStudio, a free software program for an integrated development environment for R, version 1.2.5019-6^[20].

As mentioned before, this study utilized a historical database, and participants' names and personal information were kept confidential by substituting these data for an identification number (ID). As a result, the National Committee for Ethics in Research (CONEP) waived the requirement to obtain patients' informed written consent and approved the research, which is registered in Brazil under number 2,872,543.


121 **Results**

122 The SUS Department of Information Technology (DATASUS), through a project called VinculaSUS^[19], worked on establishing a relationship among the various Ministry of Health's 123 124 databases by providing a numeric identification key (ID) which enables locating patients in 125 these various information systems and facilitates researchers' analyses of policies adopted by 126 the MoH-Brazil, while maintaining ethical commitments and the confidentiality of personal 127 data. From this relationship, a unique numeric code (ID) was attributed to each patient and this 128 code was replicated in the different databases to allow connecting the information taken from 129 different sources.

During the analyzed period, 5 million ambulatory procedures were recorded in the SIA/SUS databases, including 30,423 patients treated for hepatitis C, of which 19,100 patients were registered with laboratory tests related to hepatitis C in the GAL database. Only 11,308 of these patients had a viral load test performed 12 weeks after the end of treatment, allowing the assessment of SVR and confirming the cure of hepatitis C. Of these 11,308 patients, 10,758 had a sustained virologic response and 550 individuals continued to present detectable qPCR-HCV following treatment (Figure 1).

When comparing proportions to assess whether the percentage differences per state among the three groups of patients were statistically significant, the states of the North, Northeast and Southeast regions presented the same proportion of cases (about 30%) in the three groups mentioned above (p-value >0.05). The other states showed significant percentage 141 differences among the three groups (p-value < 0.05). This is due to the high concentration of 142 patients in the first group from the Southeast region, primarily from the state of São Paulo, 143 which represented 21.3% of the total number of patients. Although the other two groups 144 represent the majority of cases in the Southeast region, the final analyzed group show a higher 145 concentration of treatments for the states along the South-Southeast axis, translating into a 146 more heterogeneous group.

- 147 Georeferencing of the treated and cured cases was carried out and can be seen in Figure
- 148 2, which shows the concentration of treatments in the South and Southeastern states.
- 149 Figure 2. Georeferencing of cases according to patients treated for hepatitis C, and patients
- 150 who achieved viral cure, Brazil, 2015 to 2018.



151

152

Among the evaluated patients (n = 11,308), 6,459 (57.1%) were male, 4,847 (42.9%)

identified as white, 13,046 (65.8%) were between 50 and 69 years of age at the beginning of
treatment, 8,686 (43.8%) lived in the Southeast region of the country, 4,983 (44.1%) had

- 155 genotype 1b, 9,494 (84.0%), and 1,810 (16.0%) underwent treatment for 12 weeks and 24
- 156 weeks, respectively. More details are available in Table 1.
- 157 Table 1. Sociodemographic, clinical, and laboratory characteristics of patients who underwent
- 158 hepatitis C treatment, from October 2015 to July 2018 in Brazil.
- 159

			ents			
50	Characteristics	Total (N=11,308)				
50		N	%			
	Sex					
	Male	6459	57.1			
51	Female	4847	42.9			
	Ignored	2	0.0			
	race / color					
52	White	5464	48.3			
	Black	598	5.3			
	Asian	965	8.5			
2	Brown	1217	10.8			
3	Indigenous	5	0.0			
	Ignored	3059	27.1			
	age group					
4	0 to 9	0	0.0			
	10 to 19	2	0.0			
	20 to 29	71	0.6			
5	30 to 39	516	4.6			
55	40 to 49	1884	16.7			
	50 to 59	3970	35.1			
	60 to 69	3522	31.1			
6	Above 70	1343	11.9			
	Region of Residence					
	North	617	5.5			
7	Northeast	825	7.3			
	Southeast	4983	44.1			
	South	4393	38.8			
8	Center-West	490	4.3			
0	Genotypes					
	Genotype 1	56	0.5			
-	Genotype 1a	1674	14.8			
9	Genotype 1b	5395	47.7			
	Genotype 2	282	2.5			
	Genotype 3	1934	17.1			
0	Genotype 4	42	0.4			
~	Mixed Genotypes	12	0.1			
	Unknown	1913	16.9			
1	Treatment Time					
1	12 weeks	9554	84.5			
	12 weeks 24 weeks	9554 1752	64.5 15.5			
	24 weeks Unknown	2	0.0			
2	UIIKIIOWII	۷.	0.0			

173

174

175 Among those with sustained virologic responses (SVR) or positive response to DAA with a 176 undetectable qPCR-HCV at the end of treatment, 6,060 (56.3%) were male; 5,179 (48.1%) 177 identified as white; 3,759 (34.9%) had initiated treatment at the age range of 50 to 59 years; 178 4,777 (44.4%) lived in the Southeast region; 5,215 (48.15%) carried genotype 1b; and 9,554 179 (85.5%) and 1,752 (15.5%) underwent treatment for 12 weeks and 24 weeks, respectively. 180 Treatment regimens for each of the different genotypes identified in the study were evaluated 181 to verify whether the different responses were statistically significant. Genotypes 1 (without 182 subtype results), 1a, 1b, 2, 3, 4 and some mixed genotypes were present in the analyses. The 183 average rate of SVR with the use of DAAs was 95.0% and 95.9% for 12 and 24 weeks after 184 treatment, respectively (Table 2a).

Table 2A. Demographic, clinical, and laboratory characteristics of patients, and factors
associated with SVR, bivariate and multivariate analyzes.

		SV	'n							
Characteristics		No	Y	es	Bivariate analysis			Multivariate anal		analysis
	Total	(N= 550)		otal 0.758)	Odds Ratio	Confidence Interval (CI) 95%	p-value	Odds Ratio	CI 95%	p-value
	Ν	%	Ν	%						
Sex										
Male*	399	6.2	6060	93.8	-	-	-	-	-	-
Female	151	3.1	4696	96.9	0.5	(0.4; 0.6)	< 0.0001	0.5	(0.4;0.6)	< 0.0001
Unknown	0	0.0	2	100.0	0.0	-	-	0.0	-	-
Race / color										
White*	285	5.2	5179	94.8	-	-	-	-	-	-
Black	23	3.8	575	96.2	0.7	(0.5; 1.1)	0.1492	0.8	(0.5;1.3)	0.4599
Asian	50	5.2	915	94.8	1.0	(0.7; 1.4)	0.9644	1.0	(0.7;1.5)	0.8774
Brown	60	4.9	1157	95.1	0.9	(0.7; 1.3)	0.6837	1.0	(0.7;1.4)	0.8939
Indigenous	0	0.0	5	100.0	0.0	-	0.7350	0.0	-	0.9893
Unknown	132	4.3	2927	95.7	0.8	(0.7; 1.0)	0.0648	0.9	(0.7;1.1)	0.2054
Age range										
10 to 19	0	0.0	2	100.0	0.0	-	0.3587	-	-	-
20 to 29	1	1.4	70	98.6	0.3	(0.0; 2.3)	0.2503	-	-	-
30 to 39*	23	4.5	493	95.5	-	-	-	-	-	-
40 to 49	83	4.4	1801	95.6	1.0	(0.6; 1.6)	0.9595	-	-	-
50 to 59	211	5.3	3759	94.7	1.2	(0.8; 1.9)	0.4105	-	-	-
60 to 69	182	5.2	3340	94.8	1.2	(0.7; 1.8)	0.4929	-	-	-
Above 70	50	3.7	1293	96.3	0.8	(0.5; 1.4)	0.4660	-	-	-

Region of Residence

North*	37	6.0	580	94.0	-	-	-	-	-	-
Northeast	48	5.8	777	94.2	1.0	(0.6; 1.5)	0.8867	0.9	(0.5;1.4)	0.5730
Southeast	206	4.1	4777	95.9	0.7	(0.5; 1.0)	0.0332	0.8	(0.6;1.3)	0.3997
South	243	5.5	4150	94.5	0.9	(0.6; 1.3)	0.6377	1.0	(0.6;1.4)	0.8371
Center-West	16	3.3	474	96.7	0.5	(0.3;1.0)	0.0372	0.7	(0.4;1.3)	0.2121
Genotypes										
1	0	0.0	56	100.0	0.0	-	0.3004	0.0	-	0.9666
1a*	62	3.7	1612	96.3	-	-	-	-	-	-
1b	180	3.3	5215	96.7	0.9	(0.7; 1.2)	0.4705	0.9	(0.6;1.2)	0.3538
2	22	7.8	260	92.2	2.2	(1.2;3.6)	0.0022	1.5	(0.7;2.9)	0.2831
3	181	9.4	1753	90.6	2.7	(2.0; 3.6)	< 0.0001	2.8	(2.0;3.8)	< 0.0001
4	1	2.4	41	97.6	0.6	(0.1;4.7)	0.6553	0.6	(0.1;4.5)	0.6200
Mixed genotypes	0	0.0	12	100.0	0.0	-	0.9826	0.0	-	0.9844
Unknown	104	5.4	1809	94.6	1.5	(1.1;2.1)	0.0143	1.2	(0.9;1.8)	0.1968


187

In the odds ratio (OR) assessment, we verified that females are half as likely to have a negativeresponse to therapy when compared to males (Table 2a).

In relation to the variable race/color, the rates did not present significantly different values for DAA-based therapies, with positive responses between 94.8 and 100%. The age group variable presented positive responses to treatment, varying from 94.7% to 100%; however, the p-value indicated no significant differences among the groups (Table 2a).

194 The positive response rate for the five Brazilian regions ranged from 94.0 to 96.7%, being 195 significantly better in the Center-West and Southeast with an OR of 0.5 and 0.7, respectively 196 (p< 0,05). SVR proportion ranged from 90.6% (genotype 3) to 100% (genotype 1). Some 197 patients (12) were classified as infected by two different genotypes (mixed genotypes) and the 198 SVR proportion was 100%. Patients with genotypes 2 and 3 obtained the lowest SVR 199 92.2% and 90.6%, respectively. When results were assessed according to proportion: 200 genotypes, patients with genotypes 2 and 3 were 1.5 and 2.8 more likely to not have SVR, 201 respectively, when compared to genotype 1a and 1b (Table 2b and Figure 3). These results 202 were confirmed by the bivariate and multivariate analyses (Table 2a and 2b).

- 203 The treatment of genotype 1a and 1b reached results of 96.3 and 96.7%, respectively. For 56
- 204 patients with genotype 1, there were no records of the subgenotype (1a and 1b). These patients
- had a 100% positive response rate to therapy (Table 2a and Figure 3).
- **Figure 3**. HCV qPCR results, 12 weeks after treatment for HCV, according to regimen and
- 207 genotype, Brazil, 2015 to 2018.



HCV qPCR results, 12 weeks after HCV treatment by genotype

208


209

In relation to the different therapeutic regimens assessed, the positive response rate or SVR ranged from 72.4 to 100%. The response rate for the PEG+RBV regimen was significantly negative when compared to the other schemes, with an OR of 7.5 (p<0.0001). The least efficient regimen was SOF+SMV, with an OR of 1.4. We found no differences between treatment time of 12 and 24 weeks (Table 2).

When observing the data by therapeutic scheme, the results of SVR after 12 weeks of DAA-based treatment ranged from 92.2% (Sofosbuvir + RBV) to 100% (3D + Ribavirin) (Table 2 and Figure 4)

Figure 4. HCV qPCR results, 12 weeks after treatment for HCV, according to therapeutic

scheme.



220

Patients with records of any of the comorbidities detailed in Table 2b had their information analyzed (7,588 registers). The response rate ranged from 83.3% (cirrhosis /child-Pugh A) to 97,9% (CKD- Chronic Kidney Disease); however, when the bivariate analysis was conducted, only the variable "presence of neoplasm" showed a significant result, with an OR of 1.8, that is, patients with neoplasms are nearly twice more likely to not reach a cure than patients without this comorbidity (p < 0,0003) (Table 2b).

Table 2B. Demographic, clinical, and laboratory characteristics of patients, and factors associated with SVR, bivariate and multivariate analyzes.

- 229
- 230

		SV	'R							
Characteristics		No	Y	es	Bivaria	te analysis	Multivariate analysis			
	Total	(N= 550)		otal 0.758)	Odds Ratio	Confidence Interval (CI) 95%	p-value	Odds Ratio	CI 95%	p-value
	Ν	%	Ν	%						
Therapeutic scheme										
3D + RBV	0	0.0	30	100.0	0.0	-	0.4212	0.0	-	0.975
PEG + RBV	43	27.6	113	72.4	7.4	(5.1;10.8)	<	7.5	(5.0;11.2)	<
SOFO + DCV*	199	4.9	3859	95.1	-	-	0.0001	-	-	0.000
SOF + DCV + RBV	159	4.9	3835	96.0	0.8	(0.6; 1.0)	- 0.0449	0.8	(0.6; 0.9)	0.009
SOFO + PEG +										
RBV	9	4.9	175	95.1	1.0	(0.5; 2.0)	0.9938	0.5	(0.2;1.0)	0.036
SOF + RBV	29	7.8	342	92.2	1.6	(1.1;2.5)	0.0161	1.4	(0.8; 2.5)	0.221
SOF + SMV	79	4.6	1649	95.4	0.9	(0.7; 1.2)	0.5888	1.3	(1.0; 1.8)	0.0484
SOF + SMV + RBV	13	3.3	377	96.7	0.7	(0.4; 1.2)	0.1671	1.0	(0.5; 1.7)	0.9092
Unknown	16	4.8	318	95.2	1.0	(0.6; 1.6)	0.9264	1.0	(0.6; 1.8)	0.864
Others	3	4.8	60	95.2	1.0	(0.3; 3.1)	0.9587	1.2	(0.4; 3.9)	0.758
Fime of treatment										
12 weeks*	479	5.0	9075	95.0	-	-	-	-	-	-
24 weeks	71	4.1	1681	95.9	0.8	(0.6; 1.0)	0.0862	0.8	(0.6;1.1)	0.197
Unknown	0	0.0	2	100.0	0.0	-	0.3904	0.0	-	0.993
Comorbidities										
Neoplasm										
Yes*	48	8.0	551	92.0	1.8	(1.3; 2.4)	0.0003	1.7	(1.2; 2.3)	0.001
No	502	4.7	10207	95.3	1.0	(0.9;1.1)	1.0000	1.0	(0.9;1.1)	1.000
HIV Yes*	70	4.6	1461	95.4	_	_	-	_	_	
No	480	4.9	9299	95.1	1.1	(0.8; 1.4)	0.5695	-	-	-
Fibrosis/Cirrhosis										
Yes*	171	4.6	3551	95.4	-	-	-	-	-	-
No	379	5.0	7209	95.0	1.1	(0.9;1.3)	0.3524	-	-	-
Child -Pugh A			_							
Yes*	1	16.7	5	83.3	-	-	-	-	-	-
No Child-Pugh BC	549	4.9	10755	95.1	0.3	(0.0;2.2)	0.2129	-	-	-
Yes*	1	3.3	29	96.7	-	-	-	_	-	-
No	549	4,9	10731	95.1	1.5	(0.2;10.9)	0.6984	-	-	-
Fibrosis	-				-					
Yes*	7	4.5	150	95.5	-	-	-	-	-	-
No	543	4.9	10610	95.1	1.1	(0.5;2.4)	0.8126	-	-	-
HBV	_		110	0.5.5						
Yes* No	5 545	4.0	119 10641	96.0 05.1	-	-	-	-	-	-
NO Diabetes	545	4.9	10641	95.1	1.2	(0.5;3.0)	0.6659	-	-	-
Yes*	6	7.0	80	93.0	-	-	-	-	-	-
No	544	4.8	10680	95.2	0.7	(0.3; 1.6)	0.3633	-	-	-
CKD										
Yes*	3	2.1	138	97.9	-	-	-	-	-	-
No	547	4.9	10622	95.1	2.4	(0.8;7.5)	0.1406	-	-	-
Portal hypertension	1	5.0	10	04.1						
Yes* No	1 549	5.9 4.9	16 10744	94.1 95.1	-	-	-	-	-	-
NO Fransplanted	549	4.9	10/44	95.1	0.8	(0.1;6.2)	0.8452	-	-	-
Yes*	9	4.2	204	95.8	-	-	-	-	-	-
No	541	4.9	10556	95.1	1.2	(0.6; 2.3)	0.6626	-	-	-

231 Bivariate and multivariate analyses showed that genotypes 1a and 1b presented 232 significantly different results when compared to others, responding better to therapeutic 233 schemes. Genotypes 2 and 3, on the other hand, responded less to treatments when compared 234 to genotype 1a and 1b. Genotype 4 had an SVR of 97.6%, but presented no significant 235 difference due to the small number of cases. In the evaluation, it was observed that the SOF + 236 RBV scheme had a significantly lower response to HCV (SVR 92.2%; OR 1.6; IC 95% 1,1-237 2.5) along with PEG + RBV (SVR 72.4%; OR 7.4; CI 5.1-10.8). We also verified that the SOF 238 + DCV + RBV scheme yielded a higher response than the other antivirals (SVR 96%; OR 0.8; 239 CI 0.6 -1.0). The SVR of 3D+RBV was 100% (Table 2b). Table 3 shows the SVR rates according to the various therapeutic regimens and genotypes (1, 240 241 1a, 1b, 2, 3, and 4).

When the results of treatments for each genotype were analyzed, we confirmed that the best SVR rates were reached by using SOF+DAC (+/-) RBV therapeutic regimens. The same was true for patients carrying genotypes 1a and 1b, whose SVR rates ranged from 96.5 to 97.7% (IC 95-98.2%).

Table 3. HCV qPCR results following 12 weeks of treatment for hepatitis C for 11,308 patients
in Brazil, according to the therapeutic scheme and patients' genotype.

					SVR
Therapeutic scheme	Patients (N)	%	Genotypes		
				No (%)	Yes (%)
PEG+ RBV	18	0.2%	genotype 1a	38.9	61.1
	40	0.4%	genotype 1b	35	65
	5	0.0%	genotype 2	40	60
	25	0.2%	genotype 3	32	68
	68	0.6%	ignored	17.6	82.4
3D + RBV	4	0.0%	genotype 1a	-	100
with DAA	26	0.2%	genotype 1b	-	100
SOF+DAC	18	0.2%	genotype 1	-	100
	604	5.3%	genotype 1a	3.5	96.5
	1899	16.8%	genotype 1b	2.5	97.5
	20	0.2%	genotype 2	5	95
	782	6.9%	genotype 3	11.9	88.1
	31	0.3%	genotype 4	3.2	96.8
	6	0.1%	Mixed genotypes	-	100
	698	6.2%	ignored	5	95
SOF+DAC+RBV	18	0.2%	genotype 1	-	100

perpetuity. All rights reserved. No reuse allowed without permission.

genotype 1a

genotype 1b

genotype 2

genotype 3

genotype 4

Mixed genotypes

ignored

genotype 2

genotype 3

ignored

genotype 1a

genotype 1b

ignored

genotype 1

genotype 1a

genotype 1b

genotype 2

genotype 3

genotype 4

ignored

genotype 1

genotype 1a

genotype 1b

genotype 2

genotype 3

genotype 4

ignored

2.3

2.7

7.3

-

-

4.6

12.5

4.1

6.7

7.1

3.3

7.6

11.5

13

-5.5

4.4

-

-4.7

3.6

4.1

-

-

-

4.1

11.8

-

5.7

-

-

_

100

-

22.2

97.7

97.3

100

92.7

100

100

95.4

87.5

95.9

93.3

92.9

96.7

92.4

88.5

87 100

94.5 95.6

100

100 100

95.3

100

96.4

95.9

100

100

100

95.9

100

88.2

100

94.3

100

100

100

100

100

77.8

rint dair btt ·//dai for this rint in

medRxiv preprint doi: https://doi.org/10.1101/2020.10.06.20207274; this version posted October 8, 2020. The copyright ho	older fo
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the p	preprin
perpetuity	•

5.4%

15.5%

0.1%

7.9%

0.1%

0.0% 6.2%

0.1%

1.3%

0.3%

0.7%

2.2%

0.5%

0.0%

0.3%

1.7%

0.1%

0.5%

0.0%

0.3%

0.0%

0.1%

0.2%

0.0%

0.1%

0.0%

0.1%

			3	
SOF+RBV	14	0.1%	genotype 1a	
	60	0.5%	genotype 1b	
	225	2.0%	genotype 2	
	26	0.2%	genotype 3	
	46	0.4%	ignored	
SOF+SMV	10	0.1%	genotype 1	
	289	2.6%	genotype 1a	
	1147	10.1%	genotype 1b	
	3	0.0%	genotype 2	
	3	0.0%	genotype 3	
	2	0.0%	Mixed genotypes	
	274	2.4%	ignored	
SOF+SMV+RBV	6	0.1%	genotype 1	

610

1753

9

893

8

4

699

8

146

30

84

246

54

3

36

197

11

51

1

35

1

15

27

1

8

2

9

SOF+PEG-RBV

unknown therapy

other therapies

248

249

Discussion 250

251 About 11,308 patients had a viral load test performed 12 weeks after the end of treatment. The average rate of SVR with the use of DAAs was 95.0% and 95.9% for 12 and 24 252 253 weeks after treatment, respectively. It is important to highlight that the study cohort had a large 254 number of patients with advanced fibrosis, cirrhosis, or comorbidities, which is consistent with 255 the treatment protocol used from 2015 to 2018. The rates of SVR were very satisfactory, 256 demonstrating that the treatment reached a high cure rate with an average of 95.5% with DAA incorporated into SUS (87% to 100%), being the largest study carried out to date in Latin
America. Similar data were found in other studies ^[9,19,20].

259 Treatment schemes in each of the different genotypes identified in the study were 260 evaluated to compare whether the different responses were statistically significant. Among 261 those with sustained virologic responses (SVR), 56.3% were male; 48.1% identified as white; 262 34.9% had initiated treatment between 50 to 59 years of age; 44.4% lived in the Southeast 263 region; 48.15% carried genotype 1b; and 85.5% underwent treatment for 12 weeks. Genotypes 264 1 (without subtype results) 1a, 1b, 2, 3, 4 and some mixed genotypes were present in the 265 analyses. Patients with genotypes 1a and 1b showed better cure rates than others (Table 2a). 266 We also verified that treatments utilizing PEG + RBV resulted in an SVR of 72.4% and those 267 that were DAA-based, such as 3D + RBV; SOFO + DCV +/- RBV; SOFO + PEG + RBV; SOF 268 + RBV; SOF + SMV +/- RBV, obtained SVR rates ranging from 92.2 to 100%.

269 The analyses of the sociodemographic data showed that being a woman aged between 270 20 and 49 years and residing in the Southeast and Center-West regions were predictors of a 271 better response to DAA-based therapies (Table 2a). The age range 50 to 69 years yielded a 272 slightly lower response to DAAs when compared to other age groups (SVR of 94.8%), although 273 this finding was not confirmed in the bivariate analysis, and the multivariate model could not 274 be conducted (Table 2a). A large retrospective cohort study with about 17,500 patients with 275 HCV, grouped into six age groups (<55 years of age, 55-59, 60-64, 65-69, 70-74, 75 years of 276 age) and treated with DAA-based therapies in 2014/2015 found high SVR rates ranging from 277 90 to 94%, similar to those found in our study. It is worth highlighting that advanced age was 278 not a predictor for a negative response, but rather the presence of cirrhosis. It is probable that 279 in our cohort, people of more advanced age – being the largest group – had cirrhosis or 280 neoplasms and that may have influenced the relatively lower SVR rates for this age group. 281 However, when the factor age was analyzed independently, it was not a predictor of a lower

SVR in relation to other age groups, according to other published studies ^[23–25]. The positive 282 283 response rate in the five regions of the country ranged from 94.0 to 96.7%, being significantly 284 better in the Center-West and Southeast, with an OR of 0.5 and 0.7, respectively. These finding 285 are difficult to interpret, although quality of life and access to healthcare in these regions may 286 contribute to a better regional response to DAAs. The state of São Paulo accounts for a large 287 representation of patients in the Southeast region and this state is known as having a good 288 public healthcare system. On the other hand, other conditions influencing the achievement or 289 not of SVR are discussed in depth throughout this study.

290 The best therapeutic results for genotype 1a and 1b, utilizing these regimens, ranged from 96.3 291 to 96.7%, respectively. Patients with genotypes 2 and 3 obtained the lowest SVR rates (92.2%) 292 and 90.6%, respectively) and were 1.5 and 2.8 more likely to not have SVR, respectively, when compared to genotype 1a and 1b, a finding that has been confirmed in other studies ^{[19, 20, 21, 22,} 293 ^{23, 24, 25].} Genotype 4 had an SVR of 97.6%, an excellent result, but the difference cannot be 294 295 established as significant due to the small number of cases. Ferreira and collaborators evaluated 296 patients in the South region, obtaining SVR rates of 92% ^[16]. Another study including 296 297 1,002 patients treated for HCV, with genotypes 1, 2 and 3, also carried out in the South region 298 by Holzmann et al, found that even patients with liver cirrhosis achieved SVR rates ranging from 88.5% to 100% ^[27]. In another study, in which 219 patients underwent therapy with DAAs, 299 300 a high rate of SVR and excellent drug tolerability were found. Failure to achieve SVR was 301 observed mainly among patients with at least one negative response predictor: cirrhosis and/or genotypes 2 or 3^[16]. Other studies carried out in the Southeast region yielded similar data 302 [18,19,20, 21,29,30] 303

This study showed that the SOF + RBV scheme had a significantly lower response to HCV (SVR 92.2%; OR 1.6; CI 95% 1.1-2.5) along with PEG + RBV (SVR 72.4%; OR 7.4; CI 5.1-10.8). We also verified a higher response for the SOF + DCV + RBV scheme than for other

antivirals (SVR 96%; OR 0.8; CI 0.6 -1.0). The SOF+SMV regimen, with an SVR of 95.6%,
yielded values that were very similar to SOF+DCV (95.1%); The addition of RBV to both
schemes increased the rates to 96.7% and 96%, respectively (Table 2b). However, in the
multivariate analyses, the SOF+SMV scheme proved to be less effective than SOF+DCV (OR
1.3), results that have also been corroborated in other studies ^[31,32].

Although the SVR of 3D + RBV was 100%, we were not able to verify whether this result was
significant due to the small number of treated patients (Table 2b).

314 The high cure rate after using the therapeutic schemes considered in this study, with data from 315 all Brazilian states, has great relevance to demonstrate that public policies developed by the 316 Brazilian Ministry of Health, including the incorporation of therapies requiring large 317 investments, providing cure for thousands of hepatitis C patients, has brought Brazil closer to 318 the goal of eliminating the disease as a public health hazard, and over 140,000 people have 319 been treated to date. This study can help to understand the dynamics of response to therapy in 320 the Brazilian population. The average positive response with the use of DAAs ranged from 321 95.0% to 95.9%, demonstrating that it is possible to obtain good results with therapies for hepatitis C in the public health system. 322

323 Limitations

This study was conducted using, initially, secondary data collected from the Ministry of Health's information systems (DATASUS). However, in order to collect data, it was necessary to work with several independent areas of that institution, as there is no interface between the different systems. Therefore, investments to increase the performance of the Ministry's systems – in charge of so many diseases – would facilitate research and permit more efficient analyses of data by managers at all levels (municipalities, states, and the federal government).

331 Although around 80,000 treatments were distributed throughout the period of this study, 332 when the databases were merged, only 29,033 patients were found in the GAL database for 333 undergoing some hepatitis C exam while also being registered in other databases related to the 334 treatment of Hepatitis C (SIASUS - BPAI and APAC). Of these, 19,100 (66%) had qPCR-HCV in the GAL, but only 11,308 (~60%) had qPCR-HCV after 12 weeks of treatment for 335 336 hepatitis C (Figure 2). Therefore, it can be inferred that most patients may have undergone 337 testing through Supplementary Health Care (Health Insurance Plans) or bore the costs of 338 laboratory tests themselves, and therefore, were not included in the GAL system database.

Among the main limitations to this study, the incompleteness of data in all systems stands out. The main data refer toresults of viral genotype; race/color; and comorbidities (Tables 1 and 2). The study was conducted with secondary data that did not always adequately control confounding factors. The absence of sociodemographic data (resulting from poorly filled out forms), such as information about race/color (27%) is common in the various SUS databases (e,g.: GAL and Sinan- Notifiable Diseases Information System).

In the evaluated age groups, we found some differences in the SVR rate, but this was not confirmed by the bivariate analyses. SVR rates varied from 98.6 to 100% in the age group between 10 and 29 years. This indicates that there is a better response to therapy among younger populations; however, the number of patients assessed was small (73) and this positive difference in SVR could not be confirmed in the statistical models.

In relation to comorbidities, there were 7,588 registers; for the remaining patients (3,720), this variable had been left blank (absent information), a fact that may cause a bias of information as this information was absent for about 30% of the patients in this cohort. It is true that the guidelines in that period restricted SUS treatment for patients with hepatitis C who had advanced fibrosis (stages 3, 4) or those who presented some type of comorbidity. Although 355 some comorbidities are known for their negative response to therapies, such as the presence of 356 decompensated cirrhosis, the assessed data did not show significant differences in the SVR. 357 This could be intrinsically related to incorrect or absent data, which may interfere in the 358 analyses and increase bias, as mentioned above. Data related to comorbidities are exclusively 359 filled out in spreadsheets and sent to the Ministry of Health; they are not included in the 360 SIASUS system as are the others.

The only comorbidity that yielded a significantly negative difference when compared to the others (Table 2), was the presence of neoplasms (SVR of 92%; OR-1,8; p-value <0,0003). This result for people with some types of neoplasm was similar to the findings in another study ^[33]. It is important to note that, even with a poorer result when compared to others, the SVR rates are still excellent and the benefit of treating people with neoplasms is positively reported in literature, with a rate of 92% viewed as very satisfactory. ^{[24,25,34].}

367

368

369 Conclusion

370 Even without obtaining data for all patients initially located in the SIA/SUS, it is possible to conclude that the data in this study obtained excellent results, consistent with the study 371 372 performed. Brazil is also a signatory to the World Health Organization resolution and has a 373 National Plan for the Elimination of Hepatitis C as a public health hazard by 2030. One of the main goals of this plan is to offer more diagnosis and treatment for 50,000 people annually, by 374 2025 ^[13, 36]. Our work shows that the incorporation of DAAs was of prime importance to 375 376 achieve high cure rates in the studied population and highlights the importance of monitoring 377 treatments and achieving virologic cure. The Brazilian Public Health System must be included

among the public institutions that offer treatments to its population in a universal andegalitarian way.

Currently, new treatments are being incorporated into SUS, with other drugs that are as good or better than the ones we studied. Our study demonstrates that the excellent results obtained in curing patients with hepatitis C may have even better results in the future. This is significantly important, confirming the excellent results of the treatment of hepatitis C in the national territory and the need to maintain treatment for the elimination of hepatitis C as a public health problem by 2030 ^[5,14, 36].

386 Acknowledgements

We would like to acknowledge all of the support provided in the preparation and publication of this study, Brazil's Ministry of Health, DATASUS and the Department of Chronic Conditions Diseases, and other Sexually Transmitted Infections/the Ministry of Health, teams who made this study possible.

391 Authors' contributions

392 Conceptualization: SMV, WNA; Data search: SMV, RAR, WNA; Investigation: SMV,
393 RAR, WNA; Project administration: SMV, WNA; Methodology: SMV, WNA, RAR,
394 Supervision: SMV, WNA; Validation: SMV, RAR, GMJr, KCT, GFMP; Writing: SMV,
395 RAR, GMJr, GFMP, KCT; WNA; Writing-review & editing: SMV, RAR, GFMP, GMJr,
396 KCT, WNA

397 **References**

WORLD HEALTH ORGANIZATION. GLOBAL HEPATITIS REPORT, 2017. World Heal Organ.
 Geneve; 2017. Recuperado: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455 eng.pdf?sequence=1

401 2. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Global prevalence and

23

402		genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol
403		Hepatol. 2017;2: 161–176. doi:10.1016/S2468-1253(16)30181-9
404	3.	World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming
405		barriers in low- and middle-income countries. World Heal Organ. Geneva; 2018. Recuperado:
406		https://www.who.int/hepatitis/publications/hep-c-access-report-2018/en/
407	4.	Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394: 1451–1466.
408		doi:10.1016/S0140-6736(19)32320-7
409	5.	Benzaken AS, Girade R, Catapan E, Pereira GFM, de Almeida EC, Vivaldini S, et al. Hepatitis C
410		disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
411		Brazilian J Infect Dis. 2019;23: 182–190. doi:10.1016/j.bjid.2019.04.010
412	6.	Benzaken AS, Girade R, Catapan E, Pereira GFM, de Almeida EC, Vivaldini S, et al. Hepatitis C
413		disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
414		Brazilian J Infect Dis. 2019;23: 182–190. doi:10.1016/j.bjid.2019.04.010
415	7.	Ministério da Saúde-Brasil. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções.
416		2015 p. 1–98. Recuperado:
417		http://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes.pdf
418	8.	Brasil. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções.
419		Protoc Clínico e Diretrizes Ter para Hepat C e Coinfecções. Brasília, Brasil; 2015.
420		doi:10.1017/CBO9781107415324.004
421	9.	Id WL, Lin Y, Chang C, Chang C. Impact of direct-acting antiviral therapy for hepatitis C – related
422		hepatocellular carcinoma. PLOS ONE J. 2020; 80–90. doi:10.1371/journal.pone.0233212
423	10.	Gallach M, Vergara M, da Costa JP, Miquel M, Casas M, Sanchez-Delgado J, et al. Impact of treatment
424		with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS One. 2018;13: 1–15.
425		doi:10.1371/journal.pone.0208112
426	11.	Gastaldi G, Gomes D, Schneiter P, Montet X, Tappy L, Clément S, et al. Treatment with direct-acting
427		antivirals improves peripheral insulin sensitivity in nondiabetic, lean chronic hepatitis C patients. PLoS
428		One. 2019;14: 1–17. doi:10.1371/journal.pone.0217751

429 12. Juanbeltz R, Martínez-Baz I, San Miguel R, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful

430		treatment with directacting antiviral agents on health-related quality of life in chronic hepatitis C
431		patients. PLoS One. 2018;13: 1-15. doi:10.1371/journal.pone.0205277
432	13.	Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on
433		the occurrence of HCC. Liver Int. 2018;38: 139-145. doi:10.1111/liv.13659
434	14.	Ministério da Saúde B. Protocolo Clínico E Diretrizes Terapêuticas Para Hepatite C e Coinfecções.
435		Brasília; 2018.
436	15.	Brasil. Ministério da Saúde. Plano para Eliminação da Hepatite C no Brasil. Brasilia; 2018. Recuperado:
437		www.aids.gov.br
438	16.	Castelo A, Brandão Mello CE, Teixeira R, Madruga JVR, Reuter T, Pereira LMMB, et al. Hepatitis C in
439		the Brazilian public health care system: Burden of disease. Arq Gastroenterol. 2018;55: 329–337.
440		doi:10.1590/s0004-2803.201800000-74
441	17.	Perazzo H, Jorge MJ, Silva JC, Avellar AM, Silva PS, Romero C, et al. Micro-costing analysis of
442		guideline-based treatment by direct-acting agents: The real-life case of hepatitis C management in
443		Brazil. BMC Gastroenterol. 2017;17: 1-11. doi:10.1186/s12876-017-0676-8
444	18.	Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral
445		treatment for hepatitis C virus infection in adults: A systematic review. Ann Intern Med. 2013;158: 114-
446		123. doi:10.7326/0003-4819-158-2-201301150-00576
447	19.	Departamento de Informática do SUS/DATASUS-Ministério da Saúde. VinculaSUS. 2020 [citado 8 de
448		junho de 2020]. Recuperado: http://datasus1.saude.gov.br/noticias/atualizacoes/1167-datasus-demas-e-
449		hospital-albert-einstein-promovem-workshop-vinculasus
450	20.	R Foundation for Statistical. A language and environment for statistical computing. Viena/Autria; 2015.
451		Recuperado: https://www.r-project.org/
452	21.	Im GY, Dieterich DT. Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol
453		Hepatol. 2012;8.
454	22.	Daniel KE, Saeian K, Rizvi S. Real-world experiences with direct-acting antiviral agents for chronic
455		hepatitis C treatment. J Viral Hepat. 2020;27: 195–204. doi:10.1111/jvh.13218
456	23.	Reid M, Price JC, Tien PC. Hepatitis C Virus Infection in the Older Patient. Infect Dis Clin North Am.

- 457 2017;31: 827–838. doi:10.1016/j.idc.2017.07.014
- 458 24. Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of Sofosbuvir,
- 459 Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of
- 460 Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology.
- 461 2016;151: 457-471.e5. doi:10.1053/j.gastro.2016.05.049
- 462 25. Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic
- 463 hepatitis C treatment in elderly patients: A real-world study of 17 487 patients. Eur J Gastroenterol
- 464 Hepatol. 2017;29: 686–693. doi:10.1097/MEG.0000000000858
- 465 26. Ferreira VL, Borba HHL, Wiens A, Pedroso MLA, Radunz VF de C, Ivantes CAP, et al. Effectiveness
 466 and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil.
- 467 Brazilian J Infect Dis. 2018;22: 186–192. doi:10.1016/j.bjid.2018.04.003
- 468 27. Holzmann I, Tovo C V., Minmé R, Leal MP, Kliemann MP, Ubirajara C, et al. Effectiveness of chronic
 469 hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil. Brazilian J
 470 Infect Dis. 2018;22: 317–322. doi:10.1016/j.bjid.2018.06.004
- 471 28. Fernandes FF, Piedade J, Guimaraes L, Nunes EP, Chaves U, Goldenzon R V., et al. Effectiveness of
- 472 direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. J

473 Gastroenterol Hepatol. 2019;34: 2187–2195. doi:10.1111/jgh.14707

- 474 29. Lobato CM de O, Codes L, Silva GF, Souza AFM, Coelho HSM, Pedroso MLA, et al. Direct antiviral
- therapy for treatment of hepatitis C: A real-world study from Brazil. Ann Hepatol. 2019;18: 849–854.
 doi:10.1016/j.aohep.2019.08.001
- 477 30. Brasil. Ministério da Saúde. Departamento de Condições Crônicas e Infecções Sexualmente

478 Transmissíveis. In: Tratamento para as hepatites virais [Internet]. 2020 [citado 29 de maio de 2020].

- 479 Recuperado: http://www.aids.gov.br/pt-br/publico-geral/hv/o-que-sao-hepatites/tratamento-para480 hepatites-virais
- 481 31. Wang GP, Terrault N, Reeves JD, Liu L, Li E, Zhao L, et al. Prevalence and impact of baseline
 482 resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir
- 483 against GT1 HCV infection. Sci Rep. 2018;8: 1–14. doi:10.1038/s41598-018-21303-2
- 484 32. Das C Hansen KC and Tyler JK LMS. 乳鼠心肌提取 HHS Public Access. Physiol Behav. 2017;176:

485		139-148. doi:10.1016/j.physbeh.2017.03.040
486	33.	Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, et al. Sofosbuvir-
487		Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J
488		Gastroenterol. 2019;114: 250-257. doi:10.1038/s41395-018-0383-2
489	34.	El-Sayed MH, Ebeid FSES, Zekri AR, Massetto B, Kersey K, Osinusi A, et al. Ledipasvir/Sofosbuvir
490		for 12 weeks is safe and effective in adolescents with chronic hepatitis C virus infection and
491		hematological malignancies undergoing chemotherapy. J Hepatol. 2018;68: S515. doi:10.1016/s0168-
492		8278(18)31278-9
493	35.	Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the
494		elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet

495 Gastroenterol Hepatol. 2019;4: 135–184. doi:10.1016/S2468-1253(18)30270-X

496